Frederic Schynts

FIDE Capital SA is an independent wealth management firm headquartered in Brussels, Belgium. The firm was founded in 1996 as Compagnie de Gestion Privée and became FIDE Capital SA in 2012. It offers discretionary asset management services or investment advice.

Diagenode SA provides solutions for epigenetics research, biological sample preparation, and diagnostics assays. It offers Bioruptor® shearing and IP-Star® automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company was founded in 2003 and is headquartered in Seraing, Belgium.

CBRE Agency SASU provides real estate brokerage service. The company was founded on December 29, 2000 and is headquartered in Paris, France.

BioWin ASBL operates as non-profit organization, with interest in the health biotechnology sector. With its member, the firm provides support for the funding in the research and development of biomarkers, nano medicine, drug delivery system, novel therapies, medical devices, and information technology applied to human health. The company is headquartered in Gosselies, Belgium.

Labage SA engages in the development of software solutions and web-based tools for the management of technical expertise, research and development data, and resources using collective intelligence technologies. Its main product Benchsys is a software constructed as an adaptive case management system from the ground up, with the flexibility in mind and the human being right in the centre of user organization. The company was founded by Andre Renard and Christian Renard in 2002 and is headquartered in Liege, Belgium.

3d-Side SA engages in the development and production of surgical tools and software that provide surgeons with cranial implants and solutions for bone surgery. It offers bone tumor resection, skullPT, 3D (three dimension) model, and corrective osteotomy. The company was founded by Laurent Paul and Khanh Tran Duy and is headquartered in Mont-Saint-Guibert, Belgium.

TheClubDeal Capital Advisors SA (Private Equity) is a private equity/venture capital division of TheClubDeal Capital Advisors SA founded in 2016 by Nicolas de Moreau and Jean-Marc Legrand. The firm headquartered in Brussels, Belgium.

TheClubDeal Capital Advisors SA is a venture capital and private equity fund manager that invests in scale-ups and SMEs in the technology sector, both digital and industrial. The private company is based in Brussels, Belgium, and has subsidiaries in northern Belgium. TheClubDeal seeks to create alliances beyond financial investment and looks for entrepreneurs who are entirely committed to their ventures. TheClubDeal has been advising and investing in promising ventures since 2016 and has a structured deals fund of €0M and a target of €0M for its second fund, as well as a co-investment capacity target. The Belgian company was founded by Jean-Marc Legrand, who has been the CEO since its incorporation.

YUST Group NV provides real estate services. The company is based in Antwerp, Belgium and has subsidiaries in Belgium. The Belgian company was founded in 2018. Stephane Verbeeck has been the CEO of the company since 2019.

Bel V offers safety assessments and inspection services. The non-profit company is based in Brussels, Belgium. The Belgian company was founded in 2007. Michel van haesendonck has been the CEO of the company since 2018.

Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere.

THERAtRAME SA is a drug discovery start-up company based in Liege, Belgium. The Belgian company aims to become a leader in the development and positioning of novel cancer therapies by exploring new target areas to develop innovative cancer therapies. THERAtRAME's discovery platform integrates unique sets of technologies to discover, develop, and position new drugs to beat reluctant cancers. The company exploits the latest scientific discoveries highlighting the unexpected importance of trna epitranscriptomics dynamics in cancer. THERAtRAME is looking for a drug discovery assay developer leader to join their team. The company was founded by Francesca Rapino, Pierre Close, and has a team of experienced professionals with backgrounds in life sciences, medico-marketing, and biotech venture creations.